

Have you recently developed locally advanced recurrent skin cancer after a solid organ or an allogeneic bone marrow transplant in the past?



ENROLLING!

## ARTACUS STUDY

Evaluating an oncolytic immunotherapy, RPI, for advanced skin cancer in patients who have had a kidney, liver, heart, lung, and/or a hematopoietic stem cell transplant.

# Do you have advanced skin cancer after a past organ or bone marrow transplant?

If you've had a past organ or a specific type of bone marrow transplant and now have skin cancer (such as cutaneous squamous cell carcinoma [CSCC] or melanoma) that has come back and has not spread, you might want to join a research study. This study is looking at a new treatment called vusolimogene oderparepec (abbreviated as VO, also known as RPI). It is proposed to work by attacking the skin cancer cells directly while also helping your body's immune system fight the cancer.

## What is the purpose of the ARTACUS trial?

- In the ARTACUS study, we're looking for **better treatments for transplant patients like you** who have advanced skin cancers.
- Currently, there is **a need for improved treatments** compared to what's available now (surgery, radiation, targeted therapies, topical therapies, and chemotherapy).
- Some treatments, such as checkpoint inhibitors, can be risky because they might cause your body to reject the transplanted organ or bone marrow.
- We're testing RPI to see if it can **clear your skin tumors without causing rejection of your transplanted organ**.



## Am I eligible to participate?

You can join if you meet **all of the following**:

- ✓ Are 18 years old or older.
- ✓ Have cutaneous squamous cell carcinoma (CSCC) or melanoma that has come back and has not spread.
- ✓ Have at least one measurable tumor of at least 1 cm in diameter.
- ✓ Have had a kidney, liver, heart, lung, or other solid organ transplant or a bone marrow transplant.
- ✓ If your cancer has worsened after surgery or radiation and you've received one prior treatment.
- ✓ Your transplant doctor must confirm that your transplant is stable.

Your doctor can check if you fit these requirements.

**Please note that this is not the full list of conditions for joining the study.**

## What will happen if I participate in this study?

You'll be part of the study for up to 3 years, divided into three parts:

### Screening (Up to 4 weeks)

You'll have **tests and checks** to see if you can join the study.

1

### Study Treatment (About 1 year)

For about a year, you'll receive the RPI dose injected into the tumor every 2 weeks. This means you'll have up to **26 visits to the clinic during this time**. After you start treatment, you will have regular exams, imaging, and testing.

2

### Follow-Up (Up to 3 years)

After you receive your first dose, your doctor and the study team will keep an eye on you as part of this trial for up to 3 years. They'll see you **every 12 weeks** from when you got your first RPI dose.

3

## What's next?

- ✓ Check if you meet the requirements.
- ✓ Contact a clinical trial site for ARTACUS that is enrolling to find out if you may be able to join.
- ✓ Visit the [ClinicalTrials.gov](https://clinicaltrials.gov) webpage and search for NCT04349436 to know more about this study. (Scan the QR code.)
- ✓ Talk to your doctor and/or Replimune's clinical trial team if you have questions. You can call **+1 (781) 222 9570** or email [clinicaltrials@replimune.com](mailto:clinicaltrials@replimune.com)



**Important:** Vusolimogene oderparepvec (RPI) is an investigational therapy that has not been proven to be safe or approved for use by the United States Food & Drug Administration (FDA) or any other regulatory agency outside of the US.



Locations where you can join the ARTACUS study:

State	City	Institute
Arizona	Phoenix	Medical Dermatology Specialists
California	La Jolla	University of California, San Diego, Moores Cancer Center
	San Francisco	University of California San Francisco, Helen Diller Family Comprehensive Cancer Center Cutaneous Oncology
	Los Angeles	University of California, Los Angeles, Hematology/Oncology
Colarado	Aurora	University of Colorado Hospital, Anschutz Medical Pavilion
Florida	Miami	University of Miami, Sylvester Comprehensive Cancer Center
	Tampa	Moffitt Cancer Center
Illinois	Chicago	University of Chicago
New York	New York	Rochester Dermatologic Surgery
North Carolina	Durham	Duke University
Ohio	Cincinnati	University of Cincinnati Medical Center
	Columbus	Ohio State University Comprehensive Cancer Center
Pennsylvania	Pittsburgh	University of Pittsburgh Medical Center, Hillman Cancer Center
Texas	Houston	MD Anderson Cancer Center

Since the list of clinical trial sites is often updated, it is essential to refer to the latest information available. Please check the list provided above, and also consider contacting Replimune or visiting [ClinicalTrials.gov](https://ClinicalTrials.gov) webpage (NCT04349436) for the latest updates on new trial locations and how to join.



**Important:** Vusolimogene oderparepvec (RP1) is an investigational therapy that has not been proven to be safe or approved for use by the United States Food & Drug Administration (FDA) or any other regulatory agency outside of the US.